Please login to the form below

Not currently logged in
Email:
Password:

UCB to sell its US generics business for $1.5bn

Advent International and Avista Capital Partners will take control of Kremers Urban Pharmaceuticals
UCB

Belgium-based pharma company UCB has agreed to sell its generics subsidiary Kremers Urban Pharmaceuticals for $1.5bn.

The buyers are Advent International and Avista Capital Partners, both private equity firms with a healthcare focus.

UCB said it plans to use the proceeds from the sale to reduce debts and increase the company's strategic investments.

Roch Doliveux, who is due to step down as CEO of UCB, said it was “another step for UCB to enhance and focus on our core business in neurology and immunology”.

Jean-Christophe Tellier, who has been picked as Doliveux's successor, added: “Our growing core business and UCB's progressing early and late-stage pipeline now allow us to focus even more on providing innovative solutions to patients living with severe diseases.”

The transaction was unanimously approved by UCB's board of directors and is expected to close by the first quarter of 2015, subject to the satisfaction of customary closing conditions.

Detlef Thielgen, UCB's chief financial officer, said: “Kremers Urban has been an important enabler to build UCB's core business. We thank our Kremers Urban colleagues for the excellent performance they have delivered.

"It's now the right time from a value perspective to focus on our core business and to offer Kremers Urban further growth opportunities with two strong organisations that are well equipped to help Kremers Urban continue to grow.”

Article by
Kirstie Pickering

10th November 2014

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics